In 2022, puberty blockers will only be available in clinical trials. In 2021-2022, 5,000 patients were referred to this service, compared to less than 250 ten years earlier.
“Ending the routine prescribing of puberty blockers is in the best interests of the minor,” says the Secretary of State for Health. The decision comes after a significant increase in the number of patients at the specialist gender identity development service, which is to close at the end of the month. The service is one of the most important in the world.